Migraine is a frequent, disabling primary headache that manifests itself with crises lasting 4-72 hours. Typical headache characteristics are unilateral localization, pulsating character, moderate or severe intensity, worsening with routine physical activity, and association with nausea and / or photophobia and phonophobia. The diagnosis is clinical with the appearance of at least 5 seizures as described. One-third of patients may have reversible visual, sensory, or central nervous system (aura) symptoms that usually manifest before headache, but may also begin shortly after the onset of the pain phase or continue during headache.
Peptide receptor related to the calcitonin gene; Erenumab; Fremanezumab; Galcanezumab; Migraine prophylaxis
Programa d'Harmonització Farmacoterapèutica. Erenumab, fremanezumab i galcanezumab per al tractament profilàctic de la migranya. 2a ver. Barcelona: Servei Català de la Salut; 2020.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/4725.2
This item appears in following collections
The following license files are associated with this item: